11 March 2025 : Clinical Research
New-Onset, But Not Chronic Atrial Fibrillation, Is a Significant Factor Contributing to Mortality Among Patients with Severe COVID-19
Jakub Klimkiewicz
1ABDEF*, Mateusz Gutowski 1ABDE, Andrzej Michałowski1ABDE, Kamil Paryż 1ABDE, Anna Klimkiewicz2ACDEF, Arkadiusz Lubas 3ACDEF
DOI: 10.12659/MSM.946192
Med Sci Monit 2025; 31:e946192
Table 3 Comparison of chronic atrial fibrillation (CAF) group and control group.
| CAF n=50(n, %) | Control n=253(n, %) | p-value | |
|---|---|---|---|
| Age (years) | 75 SD 11.6Median 75.5IQR 16 | 63.6 SD 15.7Median 67IQR 22 | |
| Female gender | 24, 48% | 102, 40.3% | 0.313 |
| Male gender | 26, 52% | 151, 59.6% | 0.313 |
| Obesity | 12, 24% | 47, 18.6% | 0.376 |
| Diabetes | 17, 34% | 56, 22.1% | 0.073 |
| Hypertension | 33, 66% | 140, 55.3% | 0.163 |
| Ischemic heart disease | 18, 36% | 32, 12.6% | |
| Heart failure | 18, 36% | 16, 6.3% | |
| History of myocardial infarction | 8, 16% | 14, 5.4% | |
| Cerebrovascular disorders | 9, 18% | 21, 8.3% | |
| Chronic kidney disease | 13, 26% | 25, 9.9% | |
| Pulmonary embolism | 3, 6% | 16, 6.3% | 0.931 |
| ALT (U/l) | 36±2329 [9; 102]28 | 70±17639 [7; 1697]37 | 0.063 |
| AST (U/l) | 46±2349 [14; 109]33 | 94±24045 [9; 2317]41 | 0.610 |
| CRP (mg/l) | 8.1±6.27.4 [0.1; 21.1]11.1 | 10.4±8.38 [0.1; 59.2]11.4 | 0.141 |
| Ferritin (μg/l) | 886±819600 [80; 3024]711 | 1432±2024812 [21; 17118]1234 | 0.133 |
| WBC (10/l) | 10.97±9.187.95 [2.22; 46.6]7.83 | 9.87±8.037.95 [1.46; 64.85]6.06 | 0.669 |
| Urea (mg/dl) | 75 ±4069 [17; 185]64 | 64 ±5544 [7; 360]46 | |
| Albumin (g/dl) | 3.1±0.63.2 [2.1; 4.1]0.7 | 3.1±0.53.1 [1.9; 4.3]0.9 | 0.829 |
| CT scan severity index (points) | 13.2±6.714 [2; 24]13 | 14.5±5.915 [0; 25]9 | 0.330 |
| Hospital stay (days) | 12.5 Sd 10Median 11IQR 11 | 11.6 SD 7.7Median 10.3IQR9.7 | 0.601 |
| Deaths | 17, 34% | 77, 30.4% | 0.610 |